MERTK and hepatocellular carcinoma: As is shown in Figure 5, HCC patients with lower mRNA levels of RHOA (HR = 1.52, 95% CI: 1.08–2.14, P=0.016) and YBX1 (HR = 2.61, 95% CI: 1.83–3.73, P=4.3E-08) had higher overall survival (OS) (Figure 5C1,D1), while mRNA expression of CDC5L (HR = 0.84, 95% CI: 0.58–1.21, P=0.34) and MERTK (HR = 0.86, 95% CI: 0.61–1.21, P=0.38) was not associated with liver cancer patient survival (Figure 5A1,B1).